GBS, Inc. (GBS)

GBS, Inc. will go public soon, but the exact IPO date is still unknown.

Stock Price: $16.00 - $18.00

Current IPO price range

Stock Price Chart

Key Info

Market Cap	220.52M
Revenue (ttm)	n/a
Net Income (ttm)	n/a
Shares Out	12.97M
EPS (ttm)	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Dividend Yield	n/a

Stock Quote

Trading Day	n/a
Last Price	n/a
Previous Close	n/a
Change ($)	n/a
Change (%)	n/a
Day's Open	n/a
Day's Range	n/a
Day's Volume	n/a
52-Week Range	n/a

More Stats

Market Cap	220.52M
Enterprise Value	n/a
Earnings Date (est)	n/a
Ex-Dividend Date	n/a
Shares Outstanding	12.97M
Float	n/a
EPS (basic)	n/a
EPS (diluted)	n/a
FCF / Share	n/a

Dividend	n/a
Dividend Yield	n/a
Earnings Yield	n/a
FCF Yield	n/a
Payout Ratio	n/a
Shares Short	n/a
Short Ratio	n/a
Short % of Float	n/a
Beta	n/a

PE Ratio	n/a
Forward PE	n/a
P/FCF Ratio	n/a
PS Ratio	n/a
PB Ratio	n/a
Revenue	n/a
Operating Income	n/a
Net Income	n/a
Free Cash Flow	n/a

Net Cash	n/a
Net Cash / Share	n/a
Gross Margin	n/a
Operating Margin	n/a
Profit Margin	n/a
FCF Margin	n/a
ROA	n/a
ROE	n/a
ROIC	n/a

Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (0)

Buy	0
Overweight	0
Hold	0
Underweight	0
Sell	0

What these ratings mean

Analyst Consensus: n/a

Price Target

$n/a*

*No analysts have provided price targets for this stock.

Financial Performance

Financial numbers in USD.

Financial Overview

Year	2019	2018
Revenue	0	0
Net Income / Loss	-7,336,686	-5,020,383

Numbers in USD.

Company Profile

Company Details

Full Name	GBS, Inc.
Country	United States
Employees	9
CEO	Harry Simeonidis

Stock Information

Ticker Symbol	GBS
Stock Exchange	NASDAQ
Unique Identifier	NASDAQ: GBS
IPO Date	Pending

Description

GBS is a biosensor diagnostic technology company operating worldwide with our COV2 test and across the APAC Region with the biosensor platform comprising of biochemistry, immunology, tumour markers, hormones and nucleic acid diagnostic modalities. We were incorporated under the laws of Delaware on December 5, 2016. Our headquarters are located in New York, New York. GBS is the global licensee and intends to introduce and launch COV2 diagnostic tests across the US, Europe, APAC and the rest of the world through appropriately qualified distributors. Since the biosensor architecture is complete and given the pre-existing plans to develop immunology diagnostic tests, it is relatively simple and expeditious to develop the SARS-CoV-2 test.